Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Cardax, Inc. (OTC: CDXI).

Full DD Report for CDXI

You must become a subscriber to view this report.


Recent News from (OTC: CDXI)

Cardax reports Q1 results
Cardax ( OTCQB:CDXI ): Q1 EPS of -$0.01 More news on: Cardax, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 09 2018 08:10
Cardax Reports Q1 2018 Results
HONOLULU , May 9, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced its results for the first quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased almost three-fold from $107,990 in Q...
Source: PR Newswire
Date: May, 09 2018 08:00
Cardax Announces Warrant Exchange Offer
HONOLULU , May 2, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it has filed a registration statement on Form S-4 with the Securities and Exchange Commission in connection with a one-time offer to allow holders of its $0.625 warrants expiring in February 201...
Source: PR Newswire
Date: May, 02 2018 17:26
Cardax reports FY results
Cardax ( OTCQB:CDXI ): FY EPS of -$0.02 More news on: Cardax, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 27 2018 08:06
Cardax Reports 2017 Results
HONOLULU , March 27, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced its results for the year ended December 31, 2017 , the Company's first full year of sales. Revenues from ZanthoSyn ® , its premium astaxanthin dietary supplement for inflammatory health and longevity, inc...
Source: PR Newswire
Date: March, 27 2018 08:00
Cardax's ZanthoSyn® is No. 1 Seller at GNC Hawaii Stores
HONOLULU , Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that ZanthoSyn ® (60 count), the Company's premium astaxanthin dietary supplement for inflammatory health and longevity, was the top selling product in Hawaii GNC stores for the fourth quarter of 201...
Source: PR Newswire
Date: February, 17 2018 08:00
Cardax Inks Deal to Distribute ZanthoSyn® in China
HONOLULU , Feb. 17, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that it has signed a Purchase Agreement (the "Agreement") with Health Elite Club Limited ("HECL") of Hong Kong for distribution of ZanthoSyn ® , the Company's premium astaxanthin dietary supplement ...
Source: PR Newswire
Date: February, 17 2018 08:00
Cardax Hires Gilbert Shin as VP, Retail Sales and Marketing
HONOLULU , Dec. 7, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that Gilbert Shin has joined Cardax as Vice President, Retail Sales and Marketing, a new position for the Company. Mr. Shin will lead the Company's recently announced national rollout of ZanthoSyn&#x...
Source: PR Newswire
Date: December, 07 2017 08:00
ZanthoSyn® from Cardax Now Available at 3,000+ GNC Corporate Stores in the U.S.
HONOLULU , Dec. 7, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced today that ZanthoSyn ® , the Company's premium astaxanthin dietary supplement for inflammatory health and longevity, is now available at more than 3,000 corporate stores across the U.S. owned and operat...
Source: PR Newswire
Date: December, 07 2017 08:00
Cardax Refutes Allegations by Competitive Trade Group, NAXA
HONOLULU , Dec. 5, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today refuted numerous false and baseless allegations made by the Natural Algae Astaxanthin Association ("NAXA") in a "citizen" petition that it recently filed with the Food and Drug Administration ("FDA"). NAXA is a sma...
Source: PR Newswire
Date: December, 05 2017 08:00

 


About Cardax, Inc. (OTC: CDXI)

Logo for Cardax, Inc. (OTC: CDXI)

Cardax devotes substantially all of its efforts to developing and commercializing safe anti inflammatory dietary supplements and drugs. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti inflammatory without the side effects of currently marketed anti inflammatories. The safety and efficacy of Cardax s products have not been directly evaluated in clinical trials or confirmed by the FDA.

 

 

 

Current Management

  • David G. Watumull / CEO, President
  • David M. Watumull / COO, Asst. Treasurer, Asst. Secretary
  • John B. Russell / CFO, Treasurer
  • Richard M. Morris / Secretary
  • George W. Bickerstaff, III / Chairman
  • Michele Galen /
  • Terence A. Kelly, Ph.D. /
  • David G. Watumull /

Current Share Structure

  • Market Cap: $42,813,406 - 03/15/2018
  • Authorized: 400,000,000 - 03/01/2018
  • Issue and Outstanding: 122,674,516 - 03/01/2018
  • Float: 3,345,914 - 03/12/2015

 


Recent Filings from (OTC: CDXI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Registration of securities issued in business combination transactions
Filing Type: S-4Filing Source: edgar
Filing Date: May, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 05 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 13 2017
Filing Type: CT ORDERFiling Source: edgar
Filing Date: November, 07 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 20 2017

 

 


Daily Technical Chart for (OTC: CDXI)

Daily Technical Chart for (OTC: CDXI)


Stay tuned for daily updates and more on (OTC: CDXI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: CDXI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CDXI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of CDXI and does not buy, sell, or trade any shares of CDXI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/